Corvus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRVS)

$8.06 -0.06 (-0.74 %)
(As of 02/21/2018 06:24 AM ET)
Previous Close$8.12
Today's Range$7.85 - $9.13
52-Week Range$7.54 - $22.14
Volume75,300 shs
Average Volume82,500 shs
Market Capitalization$170.85 million
P/E Ratio-3.00
Dividend YieldN/A
Beta-2.39

About Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals logoCorvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520

Debt

Debt-to-Equity RatioN/A
Current Ratio10.12%
Quick Ratio10.12%

Price-To-Earnings

Trailing P/E Ratio-2.99627138932569
Forward P/E Ratio-2.86
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.35 per share
Price / Book1.27

Profitability

Trailing EPS($2.69)
Net Income$-36,370,000.00
Net MarginsN/A
Return on Equity-48.78%
Return on Assets-44.98%

Miscellaneous

Employees44
Outstanding Shares21,040,000

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.62) EPS for the quarter, topping the Zacks' consensus estimate of ($0.81) by $0.19. View Corvus Pharmaceuticals' Earnings History.

Where is Corvus Pharmaceuticals' stock going? Where will Corvus Pharmaceuticals' stock price be in 2018?

4 brokerages have issued twelve-month price objectives for Corvus Pharmaceuticals' shares. Their forecasts range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $21.67 in the next twelve months. View Analyst Ratings for Corvus Pharmaceuticals.

Who are some of Corvus Pharmaceuticals' key competitors?

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the folowing people:

  • Richard A. Miller M.D., Chairman of the Board, President, Chief Executive Officer (Age 66)
  • Leiv Lea, Chief Financial Officer (Age 63)
  • Jason V. Coloma Ph.D., Senior Vice President and Chief Business Officer (Age 41)
  • William Benton Jones Ph.D., Vice President of Pharmaceutical Development (Age 52)
  • Erik J. Verner Ph.D., Vice President of Chemistry Research (Age 52)
  • Ian T. Clark, Independent Director (Age 56)
  • Elisha P. Gould III, Independent Director (Age 60)
  • Steve E. Krognes, Independent Director (Age 48)
  • Peter Moldt Ph.D., Independent Director (Age 58)
  • Scott W. Morrison, Independent Director (Age 59)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Who owns Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.18%), Jennison Associates LLC (2.22%), Renaissance Technologies LLC (1.11%), Millennium Management LLC (0.28%), Spark Investment Management LLC (0.14%) and Goldman Sachs Group Inc. (0.12%). Company insiders that own Corvus Pharmaceuticals stock include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.

Who sold Corvus Pharmaceuticals stock? Who is selling Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC. View Insider Buying and Selling for Corvus Pharmaceuticals.

Who bought Corvus Pharmaceuticals stock? Who is buying Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Millennium Management LLC, Spark Investment Management LLC, Goldman Sachs Group Inc., SG Americas Securities LLC and Deutsche Bank AG. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.

How do I buy Corvus Pharmaceuticals stock?

Shares of Corvus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of Corvus Pharmaceuticals stock can currently be purchased for approximately $8.06.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $170.85 million. The company earns $-36,370,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Corvus Pharmaceuticals employs 44 workers across the globe.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]


MarketBeat Community Rating for Corvus Pharmaceuticals (CRVS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corvus Pharmaceuticals (NASDAQ:CRVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.67$21.67$21.67$21.67
Price Target Upside: 66.67% upside66.67% upside66.67% upside66.67% upside

Corvus Pharmaceuticals (NASDAQ:CRVS) Consensus Price Target History

Price Target History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$14.00HighView Rating Details
8/8/2017WedbushReiterated RatingOutperform$26.00MediumView Rating Details
7/4/2017CowenReiterated RatingOutperformMediumView Rating Details
4/5/2017Cantor FitzgeraldReiterated RatingBuy$25.00HighView Rating Details
6/2/2016BTIG ResearchInitiated CoverageBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageBuy$24.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Corvus Pharmaceuticals (NASDAQ:CRVS) Earnings History and Estimates Chart

Earnings by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ CRVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.81)($0.62)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.76)($0.73)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.79)ViewN/AView Earnings Details
3/10/201712/31/2016($0.52)($0.55)ViewN/AView Earnings Details
11/3/2016Q3 2016($0.45)($0.51)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.36)($0.43)ViewN/AView Earnings Details
5/5/2016Q1 2016($5.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Corvus Pharmaceuticals (NASDAQ:CRVS) Earnings Estimates

2018 EPS Consensus Estimate: ($3.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.76)($0.76)($0.76)
Q2 20181($0.89)($0.89)($0.89)
Q3 20181($1.01)($1.01)($1.01)
Q4 20181($0.85)($0.85)($0.85)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Corvus Pharmaceuticals (NASDAQ:CRVS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 46.40%
Institutional Ownership Percentage: 84.84%
Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)
Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Richard A Md MillerCEOBuy10,000$10.79$107,900.00View SEC Filing  
6/23/2017Holdings A/S NovoMajor ShareholderBuy20,000$10.95$219,000.003,244,046View SEC Filing  
6/13/2017Richard A Md MillerInsiderBuy25,000$9.88$247,000.00View SEC Filing  
6/24/2016Orbimed Advisors LlcDirectorBuy1,000$12.98$12,980.00View SEC Filing  
6/21/2016Orbimed Advisors LlcDirectorBuy38,383$12.75$489,383.25View SEC Filing  
6/16/2016Orbimed Advisors LlcDirectorBuy20,000$12.35$247,000.00View SEC Filing  
6/10/2016Peter A ThompsonDirectorBuy50,000$12.96$648,000.00View SEC Filing  
5/20/2016Orbimed Advisors LlcDirectorBuy4,716$13.09$61,732.44View SEC Filing  
5/19/2016Peter A ThompsonDirectorBuy6,800$11.77$80,036.00View SEC Filing  
5/13/2016Richard A Md MillerCEOBuy30,300$10.00$303,000.00View SEC Filing  
5/12/2016A/S NovoMajor ShareholderBuy70,000$10.00$700,000.003,224,046View SEC Filing  
3/29/2016Adams Street Partners LlcMajor ShareholderBuy200,000$15.00$3,000,000.00View SEC Filing  
3/29/2016Peter A ThompsonDirectorBuy550,000$15.00$8,250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corvus Pharmaceuticals (NASDAQ CRVS) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per ShareZacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - February 13 at 7:16 PM
Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of "Hold" by BrokeragesCorvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumCorvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
finance.yahoo.com - February 1 at 9:06 AM
Comparing AC Immune (ACIU) & Corvus Pharmaceuticals (CRVS)Comparing AC Immune (ACIU) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - January 12 at 7:04 PM
Corvus Pharmaceuticals Inc (CRVS) Expected to Post Earnings of -$0.66 Per ShareCorvus Pharmaceuticals Inc (CRVS) Expected to Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - January 10 at 9:16 PM
Corvus Pharmaceuticals (CRVS) Downgraded by Zacks Investment Research to HoldCorvus Pharmaceuticals (CRVS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 5 at 7:02 PM
 Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - December 7 at 5:28 PM
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 SharesCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 Shares
www.americanbankingnews.com - November 22 at 4:53 PM
 Analysts Anticipate Corvus Pharmaceuticals, Inc. (CRVS) to Post -$0.66 EPS Analysts Anticipate Corvus Pharmaceuticals, Inc. (CRVS) to Post -$0.66 EPS
www.americanbankingnews.com - November 19 at 7:14 PM
Corvus Pharmaceuticals Is Now Oversold (CRVS)Corvus Pharmaceuticals Is Now Oversold (CRVS)
www.thestreet.com - November 14 at 10:59 PM
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient SelectionCorvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
finance.yahoo.com - November 11 at 10:36 PM
FY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by AnalystFY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by Analyst
www.americanbankingnews.com - November 8 at 9:51 AM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - November 7 at 8:26 PM
Corvus Pharmaceuticals, Inc. (CRVS) Posts  Earnings Results, Beats Expectations By $0.19 EPSCorvus Pharmaceuticals, Inc. (CRVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - November 3 at 5:48 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program Update
www.thestreet.com - November 2 at 6:30 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
finance.yahoo.com - November 2 at 6:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Short Interest UpdateCorvus Pharmaceuticals, Inc. (CRVS) Short Interest Update
www.americanbankingnews.com - October 28 at 1:26 AM
Oversold Conditions For Corvus Pharmaceuticals (CRVS)Oversold Conditions For Corvus Pharmaceuticals (CRVS)
www.thestreet.com - October 26 at 2:44 PM
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingCorvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - October 18 at 6:54 PM
Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - October 17 at 4:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 11 at 12:04 AM
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceCorvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:20 PM
Contrasting Corvus Pharmaceuticals (CRVS) and The CompetitionContrasting Corvus Pharmaceuticals (CRVS) and The Competition
www.americanbankingnews.com - September 14 at 12:26 AM
Corvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per ShareCorvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
UPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to NeutralUPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to Neutral
www.streetinsider.com - August 24 at 5:43 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse GroupCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse Group
www.americanbankingnews.com - August 23 at 9:42 PM
 Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Announce Earnings of -$0.85 Per Share Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - August 16 at 10:16 AM
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare ConferenceCorvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 11 at 8:59 PM
FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)
www.americanbankingnews.com - August 10 at 1:16 PM
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives "Outperform" Rating from WedbushCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - August 8 at 8:56 PM
Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.s Q2 2017 Earnings (NASDAQ:CRVS)Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:CRVS)
www.americanbankingnews.com - August 7 at 7:04 AM
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues  Earnings Results, Beats Estimates By $0.03 EPSCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 5 at 2:34 PM
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business UpdateCorvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 6:59 PM
Corvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at WedbushCorvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at Wedbush
www.americanbankingnews.com - August 2 at 5:48 PM
Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS)Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - August 2 at 7:58 AM
Analyzing Corvus Pharmaceuticals (CRVS) and OncoGenex Pharmaceuticals (OGXI)Analyzing Corvus Pharmaceuticals (CRVS) and OncoGenex Pharmaceuticals (OGXI)
www.americanbankingnews.com - July 20 at 2:32 PM
Corvus Pharmaceuticals, Inc. (CRVS) to Post FY2017 Earnings of ($2.60) Per Share, Cantor Fitzgerald ForecastsCorvus Pharmaceuticals, Inc. (CRVS) to Post FY2017 Earnings of ($2.60) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - July 17 at 10:14 AM
Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-OncologyCorvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
finance.yahoo.com - July 6 at 6:48 PM
Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology ProgramCorvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
globenewswire.com - May 9 at 4:30 PM
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 10 at 5:35 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 10 at 5:35 PM
Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444
us.rd.yahoo.com - January 10 at 5:18 PM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
us.rd.yahoo.com - January 10 at 5:18 PM
4:11 pm Corvus Pharmaceuticals names Ian T. Clark to Board of Directors; Clark was the former CEO of Genetech4:11 pm Corvus Pharmaceuticals names Ian T. Clark to Board of Directors; Clark was the former CEO of Genetech
us.rd.yahoo.com - January 4 at 3:31 AM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD DisclosureCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
us.rd.yahoo.com - January 4 at 3:31 AM
Corvus Pharma (CRVS) Appoints Ian Clark to Board of DirectorsCorvus Pharma (CRVS) Appoints Ian Clark to Board of Directors
www.streetinsider.com - January 3 at 10:30 PM
ContraVir Pharma (CTRV) Announces Positive Update on CRV431 as HBV TreatmentContraVir Pharma (CTRV) Announces Positive Update on CRV431 as HBV Treatment
www.streetinsider.com - December 8 at 7:37 AM
ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis BContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B
www.prnewswire.com - December 8 at 7:37 AM
CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersCORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 8 at 7:37 AM
Corvus Pharma (CRVS) Offers Encouraging Data from CPI-444 Combo Biomarker Phase 1/1bCorvus Pharma (CRVS) Offers Encouraging Data from CPI-444 Combo Biomarker Phase 1/1b
www.streetinsider.com - October 12 at 9:10 AM

SEC Filings

Corvus Pharmaceuticals (NASDAQ:CRVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corvus Pharmaceuticals (NASDAQ:CRVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corvus Pharmaceuticals (NASDAQ CRVS) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.